150 related articles for article (PubMed ID: 24256569)
21. Pharmacokinetics and tissue distribution of deferoxamine-based nanochelator in rats.
Jones G; Zeng L; Stiles WR; Park SH; Kang H; Choi HS; Kim J
Nanomedicine (Lond); 2022 Sep; 17(22):1649-1662. PubMed ID: 36547231
[TBL] [Abstract][Full Text] [Related]
22. Oral Non-absorbable Polymer-Deferoxamine Conjugates for Reducing Dietary Iron Absorption.
Cui S; Liu Z; Nagy T; Agboluaje EO; Xiong MP
Mol Pharm; 2023 Feb; 20(2):1285-1295. PubMed ID: 36622899
[TBL] [Abstract][Full Text] [Related]
23. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
24. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
Lau EH; Cerny EA; Wright BJ; Rahman YE
J Lab Clin Med; 1983 May; 101(5):806-16. PubMed ID: 6403640
[TBL] [Abstract][Full Text] [Related]
25. Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload.
Aydinok Y; Unal S; Oymak Y; Vergin C; Türker ZD; Yildiz D; Yesilipek A
Eur J Haematol; 2012 May; 88(5):431-8. PubMed ID: 22335829
[TBL] [Abstract][Full Text] [Related]
26. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
27. Combined therapy with deferoxamine and deferiprone.
Kattamis A
Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
[TBL] [Abstract][Full Text] [Related]
28. Iron removal by desferrioxamine in patients on chronic hemodialysis--kinetic study and long-term results.
Kovarik J; Irschik H; Graf H; Woloszczuk W; Meisinger V; Linkesch W; Stummvoll HK
Contrib Nephrol; 1985; 49():44-55. PubMed ID: 3830570
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of protective effects of Danshen against iron overload-induced injury in mice.
Gao Y; Wang N; Zhang Y; Ma Z; Guan P; Ma J; Zhang Y; Zhang X; Wang J; Zhang J; Chu L
J Ethnopharmacol; 2013 Jan; 145(1):254-60. PubMed ID: 23147497
[TBL] [Abstract][Full Text] [Related]
30. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy.
Obejero-Paz CA; Yang T; Dong WQ; Levy MN; Brittenham GM; Kuryshev YA; Brown AM
J Lab Clin Med; 2003 Feb; 141(2):121-30. PubMed ID: 12577048
[TBL] [Abstract][Full Text] [Related]
31. The size-dependent efficacy and biocompatibility of hyperbranched polyglycerol in peritoneal dialysis.
Du C; Mendelson AA; Guan Q; Chapanian R; Chafeeva I; da Roza G; Kizhakkedathu JN
Biomaterials; 2014 Feb; 35(5):1378-89. PubMed ID: 24246641
[TBL] [Abstract][Full Text] [Related]
32. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts.
Selig RA; White L; Gramacho C; Sterling-Levis K; Fraser IW; Naidoo D
Cancer Res; 1998 Feb; 58(3):473-8. PubMed ID: 9458092
[TBL] [Abstract][Full Text] [Related]
33. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
[TBL] [Abstract][Full Text] [Related]
34. Evaluation and treatment of transfusional iron overload in children.
Ware HM; Kwiatkowski JL
Pediatr Clin North Am; 2013 Dec; 60(6):1393-406. PubMed ID: 24237978
[TBL] [Abstract][Full Text] [Related]
35. Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine.
Ambrus CM; Stadler I; Toumbis CA; Stadler A; Anthone S; Anthone R; DeAlarcon P; Deshpande G; Conway J; Vladutiu AO; Ambrus JL
J Med; 1999; 30(3-4):211-24. PubMed ID: 17312675
[TBL] [Abstract][Full Text] [Related]
36. Fluorene methoxycarbonyl-PEG-deferoxamine conjugates "hitchhike" with albumin in situ for iron overload therapy.
Xu L; Guan R; Yu B; Li Y; Liu H; Jiang Y
Int J Pharm; 2022 Sep; 625():122136. PubMed ID: 36029994
[TBL] [Abstract][Full Text] [Related]
37. Influence of polymer architecture on antigens camouflage, CD47 protection and complement mediated lysis of surface grafted red blood cells.
Chapanian R; Constantinescu I; Rossi NA; Medvedev N; Brooks DE; Scott MD; Kizhakkedathu JN
Biomaterials; 2012 Nov; 33(31):7871-83. PubMed ID: 22840223
[TBL] [Abstract][Full Text] [Related]
38. In vitro biological evaluation of high molecular weight hyperbranched polyglycerols.
Kainthan RK; Hester SR; Levin E; Devine DV; Brooks DE
Biomaterials; 2007 Nov; 28(31):4581-90. PubMed ID: 17688941
[TBL] [Abstract][Full Text] [Related]
39. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
40. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
